cerebral arterial blood flow and increased cell free foetal deoxyribonucleic acid in maternal circulation. In the hands of an experienced surgeon and with aid of tocolytics, ultrasonography, and cardiotocography the overall success rate of the procedure is 77% with very small risk of complications. 4 Moreover, low cost, ease of procedure, and patient preparation are the added advantages. The delay to attempt ECV at or after 37 weeks of gestation has obvious advantages like management of complications by emergency caesarean section, giving time for spontaneous version to take place with the requirement of fewer procedures. 5,6 Thus, there are some uncertainties related to the role and outcome of ECV in breech presentation. The present study aims to determine the outcome of ECV in breech presentation.
MATERIALS AND METHODFifty-nine patients with breech presentation at 34 weeks or more period of gestation were enrolled in the study. All the uncomplicated cases of singleton breech presentation at 34 weeks or more period of gestation were included. Cases of breech presentation < 34 weeks and > 40 weeks period of gestation, breech in labour, multiple gestation, severe oligohydramniosor polyhydramnios (amniotic fluid index [AFI] < 5 or > 25), cases with any contraindication to vaginal delivery, intra-uterine growth restriction, foetal anomalies and uterine malformations, cases with concomitant adverse factors like hypertensive disorders, diabetes mellitus or gestational diabetes mellitus, heart disease, previous caesarean delivery, and placenta previa or abruption placenta have been be excluded from the study. External cephalic version was carried out in selected cases after applying inclusion and exclusion criteria at or after 37 weeks of gestation. An ultrasound examination was performed to confirm the breech position, determine the AFI, and note the placental location and rule out congenital anomalies and the presence of a nuchal cord. The patient was asked to empty her bladder. A non-stress test was performed to confirm the absence of foetal heart rate abnormalities. Tocolysis terbutaline in a dosage of 0.25 mg was administered subcutaneously. The patient was placed in a slight Trendelenburg position to facilitate disengagement/mobility of the breech. After the procedure (regardless of success or failure), a non-stress test and ultrasound examination are performed to exclude foetal bradycardia and to confirm successful version.